Diabeloop and Vicentra Launch Smartphone-Controlled DBLG2 System Integrated with Dexcom G7 CGM in Europe

July 19, 2026

Press Release Hub (PA Media) UK

Overview

Diabeloop and Vicentra have jointly launched the smartphone-controlled DBLG2 system in the European market. This system integrates Vicentra’s Kaleido insulin patch pump with the Dexcom G7 continuous glucose monitoring (CGM) system to provide automated insulin delivery for individuals with Type 1 diabetes. This automated solution is expected to significantly enhance the precision and convenience of glucose management for patients, reducing the daily burden of diabetes care.

In Depth

Key Findings

Diabeloop and Vicentra have jointly introduced the smartphone-controlled DBLG2 system to the European market. This innovative system seamlessly integrates Vicentra’s Kaleido insulin patch pump with the Dexcom G7 Continuous Glucose Monitoring (CGM) device, offering an advanced automated insulin delivery solution for individuals with Type 1 diabetes. The launch marks a significant step towards enabling more precise and individually optimized glucose management, aiming to alleviate the considerable daily burden faced by patients.

Technical / Clinical Details

The DBLG2 system leverages Diabeloop’s proprietary algorithms to automatically adjust insulin dosage based on real-time glucose data acquired from the Dexcom G7 CGM. The Kaleido insulin patch pump is designed to be compact and flexible, integrating discreetly into patients’ daily lives. Patients can monitor and make necessary adjustments to the system through a dedicated smartphone application. Clinically, this integrated system has demonstrated effectiveness in reducing the risks of hypoglycemia and hyperglycemia, and improving time-in-range (TIR) metrics, with particularly strong performance in nocturnal glucose management. The algorithms continuously learn and adapt to individual physiological responses, offering personalized therapy.

Background & Context

For individuals with Type 1 diabetes, continuous and vigilant management of blood glucose fluctuations is critical, profoundly impacting their quality of life. The development of artificial pancreas systems, integrating CGMs and insulin pumps, has been at the forefront of diabetes technology advancements. The DBLG2 system directly addresses the unmet need for solutions that lighten patient burden and enable more autonomous diabetes management. Its European launch is a crucial milestone, showcasing how digital health and wearable technologies are shaping the future of diabetes care globally.

Strategic Significance & Outlook

Diabeloop and Vicentra aim to significantly improve the lives of Type 1 diabetes patients across Europe through the widespread adoption of the DBLG2 system. The companies anticipate further functional enhancements and potential expansion into other geographical regions. Such integrated systems are poised to redefine the standard of diabetes care, paving the way for more personalized and precision medicine approaches. Furthermore, the accumulation of long-term data from these systems is expected to enable further algorithm optimization and contribute to the prevention of diabetes-related complications, enhancing long-term health outcomes.

Source: https://pressreleasehub.pa.media/article/diabeloop-and-vicentra-launch-smartphone-controlled-dblg2-system-integrated-with-kaleido-insulin-patch-pump-and-dexcom-g7-cgm-now-open-for-prescription-78744.html

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.